

## Odulimomab

<b>Cat. No.:</b>	HY-P99765
<b>CAS No.:</b>	159445-64-4
<b>Target:</b>	Integrin
<b>Pathway:</b>	Cytoskeleton
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody. Odulimomab inhibits proliferation of T lymphocyte and shows protective effects against ischemia and reperfusion injury. Odulimomab can be used for the research of transplant rejection and immunological disease <sup>[1][2]</sup> .	
<b>In Vitro</b>	Odulimomab inhibits proliferation of T lymphocyte, and cytotoxicity and antibody production of T and Natural Killer (NK) cells in vitro <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Odulimomab (1.5 and 0.75 mg/kg; i.p., 1.5 mg/kg for the first treatment then followed by daily injection of 0.75 mg/kg until sacrifice) shows protective effects against ischemia and reperfusion injury, and also repairs in renal function after transplantation <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	Cynomolgus Monkeys with renal damage ischemia and kidney autotransplantation <sup>[1]</sup>
	<b>Dosage:</b>	1.5 and 0.75 mg/kg
	<b>Administration:</b>	Intraperitoneal injection; 1.5 mg/kg for the first dose and after pedicle clamping followed by daily injection of 0.75 mg/kg until sacrifice
	<b>Result:</b>	Decreased the creatinine level after ischemia and autotransplantation for 3 days and increased the potassium fraction reabsorption.

### REFERENCES

[1]. Martin X, et al. Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation. *Transplant Proc.* 2000 Mar;32(2):481.

[2]. M. Hourmant & J. P. Soullillou. Interest in an anti-LFA-1 monoclonal antibody in the prevention of reperfusion injury in kidney transplantation. *Organ Allocation* pp 215-223.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA